8FLN
Crystal structure of BTK C481S kinase domain in complex with pirtobrutinib
Summary for 8FLN
Entry DOI | 10.2210/pdb8fln/pdb |
Related | 8FLL |
Descriptor | Tyrosine-protein kinase BTK, pirtobrutinib, SULFATE ION, ... (6 entities in total) |
Functional Keywords | btk inhibitor, transferase, transferase-inhibitor complex, transferase/inhibitor |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 32739.39 |
Authors | Cedervall, E.P.,Morales, T.H.,Allerston, C.K. (deposition date: 2022-12-21, release date: 2023-03-01, Last modification date: 2023-10-25) |
Primary citation | Gomez, E.B.,Ebata, K.,Randeria, H.S.,Rosendahl, M.S.,Cedervall, E.P.,Morales, T.H.,Hanson, L.M.,Brown, N.E.,Gong, X.,Stephens, J.,Wu, W.,Lippincott, I.,Ku, K.S.,Walgren, R.A.,Abada, P.B.,Ballard, J.A.,Allerston, C.K.,Brandhuber, B.J. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood, 142:62-72, 2023 Cited by PubMed: 36796019DOI: 10.1182/blood.2022018674 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.334 Å) |
Structure validation
Download full validation report